Axicabtagene Ciloleucel,Cyclophosphamide,Fludarabine
gilead
['lymphoma', 'axi-cel']
at a median follow-up of 47.2 months, axi-cel as second-line treatment for patients with early relapsed or refractory large b-cell lymphoma resulted in significantly longer overall survival than standard care. #asco23 #asco2023
Biomedical Science that Inspires. #medicine #medtwitter #meded #Science #Research #Technology #News